NeurAxis (NASDAQ:NRXS) & Anteris Technologies Global (NASDAQ:AVR) Head to Head Contrast

Anteris Technologies Global (NASDAQ:AVR) and NeurAxis (NASDAQ:NRXS) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Anteris Technologies Global and NeurAxis, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anteris Technologies Global	1	1	3	0	2.40
NeurAxis	0	1	1	0	2.50

Anteris Technologies Global presently has a consensus price target of $14.00, suggesting a potential upside of 133.14%. NeurAxis has a consensus price target of $13.00, suggesting a potential upside of 110.70%. Given Anteris Technologies Global’s higher possible upside, research analysts clearly believe Anteris Technologies Global is more favorable than NeurAxis.

Insider and Institutional Ownership

11.8% of NeurAxis shares are held by institutional investors. 4.5% of Anteris Technologies Global shares are held by insiders. Comparatively, 21.1% of NeurAxis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

Anteris Technologies Global has a beta of 2.02, indicating that its share price is 102% more volatile than the S&P 500. Comparatively, NeurAxis has a beta of 1.39, indicating that its share price is 39% more volatile than the S&P 500.

Earnings & Valuation

This table compares Anteris Technologies Global and NeurAxis”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anteris Technologies Global	$1.91 million	306.41	-$94.14 million	($1.95)	-3.08
NeurAxis	$5.32 million	14.58	-$14.63 million	($0.78)	-7.91

NeurAxis has higher revenue and earnings than Anteris Technologies Global. NeurAxis is trading at a lower price-to-earnings ratio than Anteris Technologies Global, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Anteris Technologies Global and NeurAxis’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Anteris Technologies Global	-4,619.27%	-77.69%	-67.99%
NeurAxis	-492.76%	N/A	-641.25%

Summary

NeurAxis beats Anteris Technologies Global on 8 of the 14 factors compared between the two stocks.

About Anteris Technologies Global

Anteris Technologies Global is a medical technology company focused on developing treatments for structural heart disease, particularly aortic valve conditions. Its work centers on transcatheter heart valve technology, which is designed to replace a damaged valve through a minimally invasive procedure. The company’s lead product is the DurAVR transcatheter heart valve. It is made using Anteris’ ADAPT tissue technology, which processes bovine pericardial tissue for use in medical devices. The valve is designed to resemble the structure and function of a healthy aortic valve.

About NeurAxis

NeurAxis, Inc. (NASDAQ: NRXS) is a medical technology company focused on developing and commercializing non-invasive neuromodulation therapies for functional gastrointestinal and other nervous-system-related disorders. The company’s approach is designed to influence neural signaling through targeted electrical stimulation. NeurAxis’s principal product is IB-Stim, a prescription, percutaneous electrical nerve-field stimulation device intended for use in adolescents with functional abdominal pain associated with irritable bowel syndrome and related functional gastrointestinal disorders.